高级检索
当前位置: 首页 > 详情页

Immunogenicity of COVID-19 vaccines in solid organ transplant recipients: a systematic review and meta-analysis

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Peoples Hosp Deyang City, Dept Hepatobiliary Surg, Deyang, Peoples R China [2]Southwest Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp, Luzhou, Peoples R China [3]Jena Univ Hosp, Dept Gen Visceral & Vasc Surg, Jena, Germany [4]Univ Hosp Essen, Univ Duisburg Essen, Dept Nephrol, Essen, Germany [5]Univ Elect Sci & Technol China, Sichuan Canc Hosp, Sch Med, Chengdu, Peoples R China [6]Southwest Med Univ, Dept Clin Med, Luzhou, Peoples R China [7]4th Peoples Hosp Zigong City, Dept Hepatobiliary Surg, Zigong, Peoples R China
出处:
ISSN:

关键词: COVID-19 vaccines Immune response Immunogenicity Meat-analysis Solid organ transplant

摘要:
Background: Solid organ transplant (SOT) recipients are at increased risks of morbidity and mortality associated with COVID-19.Objectives: This study aimed to evaluate the immunogenicity of COVID-19 vaccines in SOT recipients. Data sources: Electronic databases were searched for eligible reports published from 1 December 2019 to 31 May 2022.Study eligibility criteria: We included reports evaluating the humoral immune response (HIR) or cellular immune response rate in SOT recipients after the administration of COVID-19 vaccines.Participants: SOT recipients who received COVID-19 vaccines.Assessment of risk of bias: We used the Newcastle-Ottawa scale to assess bias in case-control and cohort studies. For randomised-controlled trials, the Jadad Scale was used.Methods: We used a random-effects model to calculate the pooled rates of immune response with 95% CI. We used a risk ratio (RR) with 95% CI for a comparison of immune responses between SOT and healthy controls.Results: A total of 91 reports involving 11 886 transplant recipients (lung: 655; heart: 539; liver: 1946; and kidney: 8746) and 2125 healthy controls revealed pooled HIR rates after the 1st, 2nd, and 3rd COVID-19 vaccine doses in SOT recipients were 9.5% (95% CI, 7-11.9%), 43.6% (95% CI, 39.3-47.8%) and 55.1% (95% CI, 44.7-65.6%), respectively. For specific organs, the HIR rates were still low after 1st vaccine dose (lung: 4.4%; kidney: 9.4%; heart: 13.2%; liver: 29.5%) and 2nd vaccine dose (lung: 28.4%; kidney: 37.6%; heart: 50.3%; liver: 64.5%).Conclusions: A booster vaccination enhances the immunogenicity of COVID-19 vaccines in SOT; however, a significant share of the recipients still has not built a detectable HIR after receiving the 3rd dose. This finding calls for alternative approaches, including the use of monoclonal antibodies. In addition, lung transplant recipients need urgent booster vaccination to improve the immune response. Xinpei Chen, Clin Microbiol Infect 2023;29:441 (c) 2022 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.

语种:
高被引:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 1 区 医学
小类 | 1 区 传染病学 1 区 微生物学
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 传染病学 1 区 微生物学
JCR分区:
出版当年[2023]版:
Q1 INFECTIOUS DISEASES Q1 MICROBIOLOGY
最新[2023]版:
Q1 INFECTIOUS DISEASES Q1 MICROBIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Peoples Hosp Deyang City, Dept Hepatobiliary Surg, Deyang, Peoples R China [3]Jena Univ Hosp, Dept Gen Visceral & Vasc Surg, Jena, Germany
共同第一作者:
通讯作者:
通讯机构: [1]Peoples Hosp Deyang City, Dept Hepatobiliary Surg, Deyang, Peoples R China [*1]Department of Hepatobiliary Surgery, People's Hospital of Deyang City, Deyang, 618000, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43378 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号